Novo Nordisk ® Sema showed weight loss of 17% d well tolerated profile The GI profile appeared similar to semaglutide 2.4 monotherapy n=12 n=12 n=12 n=12 n=12 n=11 n=24 N (%) N (%) N (%) N (%) N (%) N (%) N (%) AEs 11 (92) 12 (100) 11 (92) 12 (100) 12 (100) 11 (100) 23 (96) SAEs 1 0 0 0 1 (8) 0 0 0 AwEitshlderaadwinagl to 1 (8) 0 0 1 (8) 0 0 0 GI disorders 7 (58) 10 (83) 7 (58) 10 (83) 11 (92) 9 (82) 19 (79) ri 1.2 mg, a 2.4 mg Cagri 2.4 mg, Sema 2.4 mg Cagri 4.5 mg, Sema 2.4 mg Placebo, Sema 2.4 mg Gastro-intestinal; Change in body weight is analysed using a mixed model for repeated measurements, where all changes from xed effects. Treatment and baseline body weight are nested within visit.
Download PDF file